PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
← catalyst calendarNCT05573893 · readout in 1,960 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Daiichi Sankyo.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
800estimated
Sites
109
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-09-12 | actual | When the study began enrolling |
| Primary completion | 2031-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2022-10-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Breast Neoplasms
- Breast Cancer
- Neoplasm Metastasis
Primary outcome
what the primary-completion date above is the date OFReal-world Time To Next Treatment (rwTTNT1)
measured From first dose of T-DXd until initiation of subsequent therapy or death of any cause, whichever came first, assessed up to 60 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed